01 1Concord Biotech
01 1TACROLIMUS USP (PROCESS II)
01 1India
01 1Active
01 1Complete
GDUFA
DMF Review : Complete
Rev. Date : 2020-02-11
Pay. Date : 2020-01-13
DMF Number : 34491
Submission : 2020-01-16
Status : Active
Type : II
20
Concord Biotech Ltd, based in India, is a pharmaceutical company that stands out with its certifications from FDA and EDQM.
One of their notable products is TACROLIMUS USP (PROCESS II), with a corresponding US DMF Number 34491.
Remarkably, this DMF maintains an Active status since its submission on January 16, 2020, highlighting commitment to regulatory compliance.
Their GDUFA DMF Review was successfully complete, with a review date of February 11, 2020, and payment made on January 13, 2020, indicating their dedication to facilitating drug approvals, Categorized as Type II
